Recce Phase II clinical trial reaches key dosing milestone

Recce Pharmaceuticals is nearing completion in its Phase II clinical trial for acute bacterial skin and skin structure infections
The study is designed to evaluate the efficacy of topical gel RECCE® 327 (R327G)
It is designed to treat diabetic foot infections as well as other complex bacterial infections with patient dosing on track to be completed within CY24

Special report: A Phase II clinical trial of RECCE 327 Topical Gel is nearing completion with data so far showing a strong therapeutic response.

Clinical stage biotech company Recce Pharmaceuticals (ASX:RCE) is developing a new class of synthetic anti-infectives to address unmet medical needs.

One area of focus includes Phase II acute bacterial skin and skin structure infections (ABSSSI) with single or multiple doses of RECCE 327 (R327G), a topical gel.

The study is designed to evaluate the efficacy and systemic absorption of R327G when applied directly to the infected area which also includes diabetic foot infections and other wound infections.

‘Remarkable advancement’

RCE has reached its dosing milestone with 20 of 30 patients, all meeting the primary endpoints of the study with either a cure or notable improvement after using R327G.

The data demonstrates a strong therapeutic response with no serious adverse events reported so far.

“These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies,” RCE chief medical advisor Dr Alan Dunton said.

“The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase II trial.

“Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections,” he added.

What’s on the cards moving forwards?

As the trial progresses towards completion within CY2024, RCE remains focused on delivering a pioneering, synthetic anti-infective topical therapy to address ABSSSI, a market estimated to reach US$26b by 2032.

This continuation, following the non-DSMB’s unanimous endorsement, reflects the positive trajectory of R327G’s development and supports its continued progress toward regulatory evaluation.

This article was developed in collaboration with Recce Pharmaceuticals, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.